Maxim Group Downgrades TrovaGene (TROV) to Hold; Capital Raise Needed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. AXP
7. TMUS
8. SPY
9. CVS
10. UNH

Go back to Maxim Group Downgrades TrovaGene (TROV) to Hold; Capital Raise Needed

Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results

November 9, 2017 10:33 AM EST

SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2017. The company is issuing this press release in lieu of conducting a conference call.

"We are excited by our continued clinical research advancement of PCM-075, our oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor,"... More